Aegerion Pharmaceuticals Inc.’s proposed settlement with the Department of Justice over its marketing of the homozygous familial hypercholesterolemia therapy Juxtapid includes one count related to violation of the FDA-mandated Risk Evaluation & Mitigation Strategy for the product.
The company’s May 12 announcement of a preliminary settlement with DoJ and the Securities & Exchange Commission does not get deeply into the specifics of the violations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?